ArticleVaccine2008
Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel.
Article in Vaccine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Trial
- Human leukocyte antigens and cellular immune responses to anthrax vaccine adsorbed.Infection and immunity · 2013Trial
- A genome-wide association study of host genetic determinants of the antibody response to Anthrax Vaccine Adsorbed.Vaccine · 2012Trial
- Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.Clinical and vaccine immunology : CVI · 2012Trial
- The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed.Genes and immunity · 2011Trial
- Infectious bacteria as biological warfare agents: mechanisms, epidemiological threats, and defense strategies.Frontiers in bioengineering and biotechnology · 2026Review
- Confronting the threat of bioterrorism: realities, challenges, and defensive strategies.The Lancet. Infectious diseases · 2019Review
- Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax.Antimicrobial agents and chemotherapy · 2016Article
- Vaccine protection against Bacillus cereus-mediated respiratory anthrax-like disease in mice.Infection and immunity · 2013Article
- Sortase-conjugation generates a capsule vaccine that protects guinea pigs against Bacillus anthracis.Vaccine · 2012Article
- Anthrax vaccination strategies.Molecular aspects of medicine · 2009Review
- Saccharides cross-reactive with Bacillus anthracis spore glycoprotein as an anthrax vaccine component.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
The seroconversion rates and geometric mean concentrations (GMC) of IgG anti-PA for stored sera from U.S. military personnel immunized 3, 4, and 6 times with the U.S. licensed anthrax vaccine adsorbed were studied. Anti-PA IgG concentrations were measured by ELISA. All 246 vaccinees had low but detectable pre-immunization anti-PA IgG (GMC 1.83 microg/mL). Three doses elicited a GMC of 59.92 microg/mL and a seroconversion rate of 85.3%, four doses elicited a GMC of 157.44 microg/mL and 67.9% and the sixth of 276.95 microg/mL and 45.5%, respectively. The forth dose elicited 100% seroconversion compared to the pre-immunization level. These results should facilitate comparison between different immunization schedules and new vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.